Prospects for oral replicating adenovirus-vectored vaccines - PubMed
- ️Tue Jan 01 2013
Review
Prospects for oral replicating adenovirus-vectored vaccines
Cailin Deal et al. Vaccine. 2013.
Abstract
Orally delivered replicating adenovirus (Ad) vaccines have been used for decades to prevent adenovirus serotype 4 and 7 respiratory illness in military recruits, demonstrating exemplary safety and high efficacy. That experience suggests that oral administration of live recombinant Ads (rAds) holds promise for immunization against other infectious diseases, including those that have been refractory to traditional vaccination methods. Live rAds can express intact antigens from free-standing transgenes during replication in infected cells. Alternatively, antigenic epitopes can be displayed on the rAd capsid itself, allowing presentation of the epitope to the immune system both prior to and during replication of the virus. Such capsid-display rAds offer a novel vaccine approach that could be used either independently of or in combination with transgene expression strategies to provide a new tool in the search for protection from infectious disease.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Conflict of Interest The authors have no competing financial interests to declare.
Figures

Adenovirus Capsid Structure A) Cartoon diagram of an adenovirus particle depicting capsid proteins and DNA. B) Surface model of the trimeric Ad5 hexon protein showing the HVR regions. The amino acid location of the region is located in parenthesis. Blue: HVR1 (137–181), red: HVR2 (187–193), yellow: HVR3 (211–218), green: HVR4 (247–260), purple: HVR5 (267–282), brown HVR6 (304–315), orange: HVR7 (418–428), pink: HVR8 (435–436), cyan: HVR9 (440–451). Produced using program PYMOL and PDB 3IYN [97]. C) Surface model of the trimeric Ad2 penton knob and shaft. Red: FG loop (488–515), blue: HI loop (537–549), green: IJ loop (558–572). Produced using program PYMOL and PDB 1QIU [98]. D) Map of the Ad5 hexon protein with labeled HVRs E) Map of the fiber protein with labeled β-strands in black boxes and FG, HI and IJ loops indicated with colored arrows
Similar articles
-
Gu L, Farrow AL, Krendelchtchikov A, Matthews QL. Gu L, et al. J Vis Exp. 2015 May 6;(99):e52655. doi: 10.3791/52655. J Vis Exp. 2015. PMID: 25993057 Free PMC article.
-
Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach.
Matthews QL. Matthews QL. Mol Pharm. 2011 Feb 7;8(1):3-11. doi: 10.1021/mp100214b. Epub 2010 Dec 1. Mol Pharm. 2011. PMID: 21047139 Free PMC article. Review.
-
Lanzi A, Ben Youssef G, Perricaudet M, Benihoud K. Lanzi A, et al. Vaccine. 2011 Feb 4;29(7):1463-71. doi: 10.1016/j.vaccine.2010.12.025. Epub 2010 Dec 22. Vaccine. 2011. PMID: 21184856
-
Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach.
Matthews QL, Yang P, Wu Q, Belousova N, Rivera AA, Stoff-Khalili MA, Waehler R, Hsu HC, Li Z, Li J, Mountz JD, Wu H, Curiel DT. Matthews QL, et al. Virol J. 2008 Aug 21;5:98. doi: 10.1186/1743-422X-5-98. Virol J. 2008. PMID: 18718011 Free PMC article.
-
Progress on adenovirus-vectored universal influenza vaccines.
Xiang K, Ying G, Yan Z, Shanshan Y, Lei Z, Hongjun L, Maosheng S. Xiang K, et al. Hum Vaccin Immunother. 2015;11(5):1209-22. doi: 10.1080/21645515.2015.1016674. Hum Vaccin Immunother. 2015. PMID: 25876176 Free PMC article. Review.
Cited by
-
Aldossary AM, Ekweremadu CSM, Offe IM, Alfassam HA, Han S, Onyali VC, Ozoude CH, Ayeni EA, Nwagwu CS, Halwani AA, Almozain NH, Tawfik EA. Aldossary AM, et al. Saudi Pharm J. 2022 Jun;30(6):655-668. doi: 10.1016/j.jsps.2022.03.010. Epub 2022 Mar 15. Saudi Pharm J. 2022. PMID: 35812139 Free PMC article. Review.
-
Fougeroux C, Turner L, Bojesen AM, Lavstsen T, Holst PJ. Fougeroux C, et al. J Immunol. 2019 Apr 15;202(8):2320-2331. doi: 10.4049/jimmunol.1801210. Epub 2019 Mar 4. J Immunol. 2019. PMID: 30833346 Free PMC article.
-
Targeting adeno-associated virus and adenoviral gene therapy for hepatocellular carcinoma.
Wang YG, Huang PP, Zhang R, Ma BY, Zhou XM, Sun YF. Wang YG, et al. World J Gastroenterol. 2016 Jan 7;22(1):326-37. doi: 10.3748/wjg.v22.i1.326. World J Gastroenterol. 2016. PMID: 26755879 Free PMC article. Review.
-
Wu WH, Alkutkar T, Karanam B, Roden RB, Ketner G, Ibeanu OA. Wu WH, et al. Virol J. 2015 Sep 11;12:140. doi: 10.1186/s12985-015-0364-7. Virol J. 2015. PMID: 26362430 Free PMC article.
-
Ye X, Xiao L, Zheng X, Wang J, Shu T, Feng Y, Liu X, Su W, Wang Q, Li C, Chen L, Feng L. Ye X, et al. Front Microbiol. 2018 Dec 10;9:3040. doi: 10.3389/fmicb.2018.03040. eCollection 2018. Front Microbiol. 2018. PMID: 30619131 Free PMC article.
References
-
- Bourinbaiar AS, Metadilogkul O, Jirathitikal V. Mucosal AIDS vaccines. Viral Immunol. 2003;16(4):427–45. - PubMed
-
- Silin DS, et al. Oral vaccination: where we are? Expert Opin Drug Deliv. 2007;4(4):323–40. - PubMed
-
- FDA. Complete List of Vaccines Licensed for Immunization and Distribution in the United States. 2013 [cited 2013 April 26, 2013]; Available from: http://www.fda.gov/BiologicsBloodVaccines/default.htm.
-
- Lycke N. Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol. 2012;12(8):592–605. - PubMed
-
- Takafuji ET, et al. Simultaneous administration of live, enteric-coated adenovirus types 4, 7 and 21 vaccines: safety and immunogenicity. J Infect Dis. 1979;140(1):48–53. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical